Default company panoramic image

Asceneuron SA

Asceneuron will develop novel therapeutics for Alzheimer’s disease and tauopathies to become a leader for neurodegeneration drug discovery

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chemin de Pierrefleur, Lausanne, VD, Switzerland
  • Currency EUR
  • Founded October 2012
  • Employees 8
  • Website

Company Summary

Asceneuron will develop effective therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in drug discovery for neurodegenerative diseases. Current treatments for Alzheimer’s disease provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines.


  • Default avatar
    Dirk Beher
    Chief Scientific Officer

  • Default avatar
    Christoph Wiessner
    Head of Discovery

  • Default avatar
    Frank Armstrong
    Executive Chairman of the Board & Advisor

Previous Investors

  • Default avatar
    Merck Serono Ventures